Welcome to our dedicated page for Design Therapeutics news (Ticker: DSGN), a resource for investors and traders seeking the latest updates and insights on Design Therapeutics stock.
Design Therapeutics, Inc. (DSGN) is a clinical-stage biopharmaceutical company advancing novel therapies for genetic disorders through its proprietary GeneTAC™ platform. This page serves as the definitive source for official company announcements, research developments, and regulatory updates.
Investors and industry observers will find timely updates on clinical trial progress, partnership announcements, and scientific milestones across DSGN's pipeline targeting Friedreich ataxia, Fuchs endothelial dystrophy, and other degenerative genetic conditions. Our curated news collection provides:
• Clinical development updates
• Regulatory filings and approvals
• Research collaboration announcements
• Financial reporting disclosures
Bookmark this page for direct access to verified information about DSGN's innovative approach to gene-targeted therapies. Check regularly for new developments in genomic medicine and therapeutic advancements.
Design Therapeutics (DSGN) announced it will present Phase 1 safety data for its DT-168 program at Eyecelerator @ Park City 2025 on May 2, 2025. The presentation will cover findings from single- and multiple-ascending dose trials in healthy adult volunteers and outline Phase 2 development plans for Fuchs endothelial corneal dystrophy (FECD) patients.
DT-168 is a GeneTAC® small molecule delivered as an eye drop, designed to target CTG repeat expansion in the TCF4 gene and reduce mutant gene product expression that causes corneal endothelial cell dysfunction in FECD. The company aims to develop the first disease-modifying treatment for FECD, a progressive corneal disease that currently often requires corneal transplant surgery.
Design Therapeutics (DSGN) has appointed Chris M. Storgard, M.D. as Chief Medical Officer. Dr. Storgard brings over 20 years of drug development leadership experience, having successfully advanced multiple assets from preclinical stages through global regulatory approvals.
Prior to joining Design, Dr. Storgard served as CMO at ADARx Pharmaceuticals, Heron Therapeutics, and Fate Therapeutics. At Ardea Biosciences (an AstraZeneca Company), he led the global clinical program for lesinurad, achieving regulatory approvals in the US and Europe. His career includes roles at Biogen Idec, Amgen, Mayo Clinic, Scripps Mercy Hospital, and The Scripps Research Institute.
Design Therapeutics is advancing its portfolio of GeneTAC® small molecules, including DT-216P2 for Friedreich ataxia, focusing on treatments for serious degenerative genetic diseases.
Design Therapeutics (DSGN) has reported significant progress in its GeneTAC® programs and financial results for Q4 and full year 2024. The company has initiated a Phase 1 Single Ascending Dose trial of DT-216P2 in healthy volunteers for Friedreich Ataxia (FA), with patient dosing planned for mid-2025. Dosing is complete in the DT-168 Phase 1 healthy volunteer trial for Fuchs Endothelial Corneal Dystrophy (FECD), with data expected in H1 2025.
The company has achieved its enrollment target for the FECD observational study with 250 patients. Additionally, Design expects to select a development candidate for Myotonic Dystrophy Type-1 (DM1) in 2025.
Financial highlights include:
- R&D expenses: $12.2M for Q4 2024, $44.4M for full year
- G&A expenses: $4.5M for Q4 2024, $18.0M for full year
- Net loss: $13.7M for Q4 2024, $49.6M for full year
- Cash position: $245.5M as of December 31, 2024
Design Therapeutics (Nasdaq: DSGN), a clinical-stage biotechnology company focused on developing treatments for serious degenerative genetic diseases, has announced its upcoming participation in Leerink's Global Healthcare Conference. The company's management will engage in a fireside chat scheduled for March 10, 2025, at 1:40 p.m. ET in Miami.
The event will be accessible through a live webcast, available on the company's website at www.designtx.com in the investors section. The presentation recording will remain archived and available for viewing for a minimum of 30 days following the event.
Design Therapeutics (Nasdaq: DSGN), a clinical-stage biotechnology company focused on developing treatments for serious degenerative genetic diseases, has announced its participation in two major investor conferences. The company will present at the 2024 Jefferies London Healthcare Conference on November 19, 2024, at 10:00 a.m. GMT in London, and participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 11:30 a.m. ET in New York. Live webcasts will be available on the company's website and archived for at least 30 days after the presentations.
Design Therapeutics (NASDAQ: DSGN) announced its Q3 2024 financial results and pipeline updates. The company initiated a Phase 1 trial for FECD with data expected in H1 2025, and plans to start a Phase 1 trial for Friedreich Ataxia in H1 2025. The company reported R&D expenses of $11.9M, G&A expenses of $4.4M, and a net loss of $13.0M for Q3 2024. With $254.1M in cash and securities, Design Therapeutics expects to fund operations into 2029, supporting up to four potential clinical proof-of-concept data sets. The company is also advancing preclinical programs in Huntington's Disease and Myotonic Dystrophy Type-1.
Design Therapeutics (Nasdaq: DSGN), a biotech company focused on developing treatments for serious degenerative genetic diseases, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's management will engage in a fireside chat on Thursday, September 19, 2024, at 12:45 p.m. ET in New York.
Investors and interested parties can access a live webcast of the fireside chat through a provided link and on the company's website at www.designtx.com in the investors section. The webcast will remain archived for at least 30 days after the presentation, allowing for later viewing.
This participation in a major healthcare conference highlights Design Therapeutics' commitment to engaging with the investment community and sharing updates on their progress in developing innovative treatments for genetic diseases.
Design Therapeutics (Nasdaq: DSGN) reported its Q2 2024 financial results and provided updates on its GeneTAC™ portfolio. Key highlights include:
1. Friedreich Ataxia (FA) program DT-216P2 on track for patient trials in 2025.
2. Fuchs Endothelial Corneal Dystrophy (FECD) candidate DT-168 advancing to Phase 1 in 2024.
3. Ongoing research in Myotonic Dystrophy Type-1 (DM1) and Huntington's Disease (HD).
4. Q2 2024 financial results: R&D expenses $10.5M, G&A expenses $4.5M, net loss $11.8M.
5. Strong cash position of $261.0M, expected to fund operations into 2029.
The company aims to generate clinical proof-of-concept data across its portfolio, addressing serious degenerative genetic diseases with novel small molecule therapies.
Design Therapeutics announced their first quarter 2024 financial results and upcoming program milestones. They are advancing a new drug product for Friedreich Ataxia and Fuchs Endothelial Corneal Dystrophy towards clinical trials. The company is progressing pipeline programs for Huntington’s Disease and Myotonic Dystrophy Type-1. Design Therapeutics also highlighted their cash and securities of $270.7 million, supporting multi-year operating runway.
FAQ
What is the current stock price of Design Therapeutics (DSGN)?
What is the market cap of Design Therapeutics (DSGN)?
